The prognosis of patients treated with everolimus for advanced ER‐positive, HER2‐negative breast cancer is driven by molecular features

• Main Authors: Hélène Salaün (Author), Lounes Djerroudi (Author), Laura Haik (Author), Anne Schnitzler (Author), Guillaume Bataillon (Author), Gabrielle Deniziaut (Author), Ivan Bièche (Author), Anne Vincent‐Salomon (Author), Marc Debled (Author), Paul Cottu (Author)
• Formato: Libro
• Publicado: Wiley, 2024-05-01T00:00:00Z.
• Subjects: article
• Acceso en liña: Connect to this object online.

Abstract Everolimus is widely used in patients with advanced ER‐positive, HER2‐negative breast cancer. We looked at alterations in the PIK3CA/AKT/mTOR pathway in a multicenter cohort as potential biomarkers of efficacy. Patients with advanced ER‐positive, HER2‐negative breast cancer treated with eve...